Pfizer discussing $5 billion acquisition of GBT - report - Breaking The News

Pfizer discussing $5 billion acquisition of GBT - report

5 August

1 min read

EPA/ANDREW GOMBERT

Pfizer Inc. is negotiating a potential acquisition of Global Blood Therapeutics Inc., The Wall Street Journal reported on Friday, citing unnamed sources with knowledge of the talks.

The discussions over a $5 billion deal are in an advanced stage and Pfizer is looking to reach an agreement in the coming days, the insiders claimed.

Global Blood Therapeutics is best known for its sickle cell disease treatment Oxbryta. The company is scheduled to release second-quarter earnings on Monday, August 8.

mergers and acquisitions pfizer

Related Stocks

Global Blood Ther...

Pfizer

OpenAi allegedly in talks to buy AI startup Windsurf for $3B

16 April

OpenAI Inc. is currently in talks to acquire the AI coding assistant for developers Windsurf, formerly known as Codeium, for nearly $3 billion, a source briefed on the talks told CNBC on Wednesday. If the transaction with Windsurf goes through, this would be OpenAI's largest acquisition in an attempt to stay at the forefront of the generative AI race, competing with key rivals such as Anthropic, Elon Musk's xAI and Google.Earlier in the day, OpenAI launched its latest AI...

Elliot allegedly takes $1.2 billion stake in HPE

15 April

Elliott Management is taking a stake worth more than $1.15 billion in Hewlett Packard Enterprise, CNBC reported Tuesday, citing people familiar with the matter.According to the report, the investment firm plans to engage with HPE leadership to explore strategies for enhancing shareholder value. Elliott Management has not yet detailed its proposals but is reportedly seeking constructive discussions with the company.Hewlett Packard Enterprise Company's...

Intel to sell 51% stake in Altera to Silver Lake

14 April

Intel Corp. announced on Monday that it is selling 51% of its Altera Corp. business to Silver Lake Technology Management L.L.C. The deal values Altera at $8.75 billion and establishes its operational independence, according to the statement. The transaction is expected to close in the second half of 2025.Altera will also see a change in leadership, with CEO Sandra Rivera being replaced by Raghib Hussain on May 5. "Backed by Silver Lake’s strong track record and...

Pfizer ends weight loss pill trial after liver injury in one patient

14 April

Pfizer Inc. announced on Monday that it is halting the development of its daily pill for chronic weight management, danuglipron, after one of the participants in the trial experienced drug-induced liver injury.The company stated that a participant in one of the dose-optimization studies experienced a liver enzyme elevation but did not have any liver-related symptoms or side effects. The enzymes returned to their normal levels once the patient stopped taking the...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.